tetano
Editor, Senior Moderator
Clin Kidney J
. 2021 Dec 9;15(3):369-371.
doi: 10.1093/ckj/sfab265. eCollection 2022 Mar.
Long-term effect of COVID-19 infection on hemodialysis patients: Should we follow hemodialysis patients more closely?
Atalay Demiray[SUP] 1 [/SUP], Asiye Kanbay[SUP] 2 [/SUP], Mehmet Kanbay[SUP] 3 [/SUP]
Affiliations
Abstract
During the coronavirus disease 2019 (COVID-19) pandemic, hemodialysis patients constitute one of the most vulnerable patient populations as they have more significant comorbidities and need to visit healthcare settings frequently even under pandemic conditions. It was also largely demonstrated that hemodialysis patients have high mortality rates with severe to fatal disease due to COVID-19 during their initial hospitalization. Even though the functional decline and fatigue after severe infections are not a novel entity, some long-term effects of COVID-19 have drawn attention with their prolonged effects even after discharge. A recent prospective, observational study by Carriazo et al. provided the first evidence to compare long-term mortality rates of hemodialysis patients with and without COVID-19. Carriazo et al. stated a hazard ratio of 3.00 for the mortality rates of hemodialysis patients over a 1-year follow-up period after their COVID-19 diagnosis. They emphasized that the high mortality rates of hemodialysis patients with COVID-19 are not limited to the initial hospitalization period but also continue after discharge, especially in the first 3 months. In light of this study, it can be recommended that hemodialysis patients with COVID-19 should be monitored closely and continuously, and hemodialysis patients should be prioritized for vaccination against COVID-19 with close follow-up for their antibody levels.
Keywords: COVID-19; anti-SARS-CoV-2 antibodies; hemodialysis; mortality; outcomes.
. 2021 Dec 9;15(3):369-371.
doi: 10.1093/ckj/sfab265. eCollection 2022 Mar.
Long-term effect of COVID-19 infection on hemodialysis patients: Should we follow hemodialysis patients more closely?
Atalay Demiray[SUP] 1 [/SUP], Asiye Kanbay[SUP] 2 [/SUP], Mehmet Kanbay[SUP] 3 [/SUP]
Affiliations
- PMID: 35198153
- PMCID: PMC8689791
- DOI: 10.1093/ckj/sfab265
Abstract
During the coronavirus disease 2019 (COVID-19) pandemic, hemodialysis patients constitute one of the most vulnerable patient populations as they have more significant comorbidities and need to visit healthcare settings frequently even under pandemic conditions. It was also largely demonstrated that hemodialysis patients have high mortality rates with severe to fatal disease due to COVID-19 during their initial hospitalization. Even though the functional decline and fatigue after severe infections are not a novel entity, some long-term effects of COVID-19 have drawn attention with their prolonged effects even after discharge. A recent prospective, observational study by Carriazo et al. provided the first evidence to compare long-term mortality rates of hemodialysis patients with and without COVID-19. Carriazo et al. stated a hazard ratio of 3.00 for the mortality rates of hemodialysis patients over a 1-year follow-up period after their COVID-19 diagnosis. They emphasized that the high mortality rates of hemodialysis patients with COVID-19 are not limited to the initial hospitalization period but also continue after discharge, especially in the first 3 months. In light of this study, it can be recommended that hemodialysis patients with COVID-19 should be monitored closely and continuously, and hemodialysis patients should be prioritized for vaccination against COVID-19 with close follow-up for their antibody levels.
Keywords: COVID-19; anti-SARS-CoV-2 antibodies; hemodialysis; mortality; outcomes.